Inhibitor Therapeutics, Inc.
INTI
Rank in Stocks
#27690
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Share Price
$0.08
Last synced: 2026-11-10
Market Cap
$13.86M
Change (1 day)
1.27%
Change (1 year)
60.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Inhibitor Therapeutics, Inc. (INTI)
Category
Healthcare
EPS for Inhibitor Therapeutics, Inc. (INTI)
EPS as of June 2026 TTM: $-0.02
According to Inhibitor Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.02, equal to its 2024 EPS of $-0.02.
EPS history for Inhibitor Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -4.50% |
| 2025 | $-0.02 | -1.55% |
| 2024 | $-0.02 | -3.00% |
| 2023 | $-0.02 | -161.54% |
| 2022 | $0.03 | -2,600.00% |
| 2021 | 0.00 | -53.57% |
| 2020 | 0.00 | -61.64% |
| 2019 | $-0.01 | -40.65% |
| 2018 | $-0.01 | -11.51% |
| 2017 | $-0.01 | -42.56% |
| 2016 | $-0.02 | 42.35% |
| 2015 | $-0.02 | -59.04% |
| 2014 | $-0.04 | -58.50% |
| 2013 | $-0.10 | -829.93% |
| 2012 | $0.01 | -172.87% |
| 2011 | $-0.02 | -81.20% |
| 2010 | $-0.10 | -67.74% |
| 2009 | $-0.31 | -81.55% |
| 2008 | $-1.68 | 211.11% |
| 2007 | $-0.54 | 54.29% |
| 2006 | $-0.35 | -1,850.00% |
| 2005 | $0.02 | -116.67% |
| 2004 | $-0.12 | 300.00% |
| 2003 | $-0.03 | -89.66% |
| 2002 | $-0.29 | -64.20% |
| 2001 | $-0.81 | 58.82% |
| 2000 | $-0.51 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.99 | 5,083.25% |
US
|
|
| $15.66 | -82,089.53% |
US
|
|
| $-7.07 | 36,915.71% |
US
|
|
| $-5.29 | 27,596.34% |
AU
|
|
| $12.88 | -67,535.08% |
BE
|
Questions about Inhibitor Therapeutics, Inc.'s earnings per share (EPS)
What is Inhibitor Therapeutics, Inc.'s earnings per share (EPS)?
Inhibitor Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was Inhibitor Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Inhibitor Therapeutics, Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.02 in 2024.
How has Inhibitor Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Inhibitor Therapeutics, Inc.'s earnings per share (EPS) was highest in 2022 ($0.03) and lowest in 2025 ($-0.02).
How does Inhibitor Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Inhibitor Therapeutics, Inc.'s earnings per share (EPS) ($-0.02) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.